Leader in NOX therapies;based on the selective inhibition of NOX enzymes
GenKyoTex has raised €55M across 5 funding rounds from 3 investors, most recently a Series D+ round in Jan 2015. Based in Plan-les-Ouates, Switzerland; founded 2006; active in Healthtech. Acquired by Calliditas Therapeutics in 2014. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-01-01 | Series D+ | €17M | BioMed Partners,VI Partners | View deal → |
| 2012-07-01 | Series C | €21M |
| View deal → |
| 2011-05-01 | Series C | €14M | MP Healthcare Venture Management | View deal → |
| 2008-05-01 | Early VC | €2.4M | — | View deal → |
| 2006-01-01 | Early VC | €1.3M | — | View deal → |
